In April 2019, we expanded our range of evidence to include the genome-wide CRISPR–Cas9 dropout screens conducted by Behan et al. (23). This collaborative Open Targets study performed 941 fitness screens in 339 cancer cell lines targeting 18 009 genes. Moreover, a prioritisation framework designated ‘Project Score’ was developed to integrate cell fitness effects, genomic biomarkers and target tractability, to systematically prioritise new cancer targets (https://score.depmap.sanger.ac.uk/). A minimum target priority score of 40 is used (based on scores calculated for targets with approved or preclinical cancer compounds), providing a dataset of synthetic-lethality evidence for the association between 623 genes and 19 cancer types (Supplementary Figure S1).
